Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin

Journal of Clinical Lipidology

Volumn 5, Issue 1, 2011, Pages 50-56

  Ryu, Sung Kee ^a   Hutten, Barbara A ^b   Vissers, Maud N ^b   Wiegman, Albert ^b   Kastelein, John J P ^b   Tsimikas, Sotirios ^c  

^a Eulji University   (South Korea)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Familial hypercholesterolemia; Lipoproteins; Phospholipases; Statins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIBLING; TREATMENT DURATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; CAROTID ARTERIES; CASE-CONTROL STUDIES; CHILD; DOUBLE-BLIND METHOD; ENZYME ASSAYS; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; PRAVASTATIN; SIBLINGS; TUNICA INTIMA;

EID: 79151473875     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.11.001     Document Type: Article

References (39)

1. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group JAMA 264 1990 3018 3024
2. G.S. Berenson, W.A. Wattigney, and R.E. Tracy Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study) Am J Cardiol 70 1992 851 858
3. S. Tsimikas, and J.L. Witztum Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century J Am Coll Cardiol 40 2002 2122 2124
4. Y. Aggoun, D. Bonnet, and D. Sidi Arterial mechanical changes in children with familial hypercholesterolemia Arterioscler Thromb Vasc Biol 20 2000 2070 2075
5. M.M. Engler, M.B. Engler, and M.J. Malloy Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial Circulation 108 2003 1059 1063
6. M. Mietus-Snyder, and M.J. Malloy Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy J Pediatr 133 1998 35 40
7. J. Rodenburg, M.N. Vissers, and A. Wiegman Statin treatment in children with familial hypercholesterolemia: the younger, the better Circulation 116 2007 664 668
8. A. Wiegman, B.A. Hutten, and E. de Groot Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial JAMA 292 2004 331 337
9. A. Wiegman, E. de Groot, and B.A. Hutten Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia Lancet 363 2004 369 370
10. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
11. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
12. H.J. Avis, M.N. Vissers, E.A. Stein, F.A. Wijburg, M.D. Trip, J.J. Kastelein, and B.A. Hutten A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia Arterioscler Thromb Vasc Biol 27 2007 1803 1810
13. S. de Jongh, M.R. Lilien, J. op't Roodt, E.S. Stroes, H.D. Bakker, and J.J. Kastelein Early statin therapy restores endothelial function in children with familial hypercholesterolemia J Am Coll Cardiol 40 2002 2117 2121
14. C.H. Macphee, and J.J. Nelson An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction Eur Heart J 26 2005 107 109
15. D.M. Stafforini Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2) Cardiovasc Drugs Ther 23 2009 73 83
16. S. Tsimikas, L.D. Tsironis, and A.D. Tselepis New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease Arterioscler Thromb Vasc Biol 27 2007 2094 2099
17. F.D. Kolodgie, A.P. Burke, and K.S. Skorija Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis Arterioscler Thromb Vasc Biol 26 2006 2523 2529
18. C.A. Garza, V.M. Montori, J.P. McConnell, V.K. Somers, I.J. Kullo, and F. Lopez-Jimenez Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review Mayo Clin Proc 82 2007 159 165
19. M.S. Sabatine, D.A. Morrow, and M. O'Donoghue Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease Arterioscler Thromb Vasc Biol 27 2007 2463 2469
20. A. Thompson, P. Gao, and L. Orfei Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
21. V.G. Saougos, A.P. Tambaki, and M. Kalogirou Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243
22. C. Blencowe, A. Hermetter, G.M. Kostner, and H.P. Deigner Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein J Biol Chem 270 1995 31151 31157
23. S.A. Karabina, M.C. Elisaf, J. Goudevenos, K.C. Siamopoulos, D. Sideris, and A.D. Tselepis PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro Atherosclerosis 125 1996 121 134
24. B. Ky, A. Burke, and S. Tsimikas The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am Coll Cardiol 51 2008 1653 1662
25. M. O'Donoghue, D.A. Morrow, and M.S. Sabatine Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial Circulation 113 2006 1745 1752
26. W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress Arterioscler Thromb Vasc Biol 26 2006 1586 1593
27. J. Rodenburg, M.N. Vissers, and A. Wiegman Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin J Am Coll Cardiol 47 2006 1803 1810
28. W. Koenig, and N. Khuseyinova Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence Cardiovasc Drugs Ther 23 2009 85 92
29. S. Tsimikas, J. Willeit, and M. Knoflach Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur Heart J 30 2009 107 115
30. R.S. Rosenson Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease Cardiovasc Drugs Ther 23 2009 93 101
31. P.W. Serruys, H.M. Garcia-Garcia, and P. Buszman Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
32. I. Gazi, E.S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A.D. Tselepis Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma Clin Chem 51 2005 2264 2273
33. M.H. Davidson, M.A. Corson, M.J. Alberts, J.L. Anderson, P.B. Gorelick, P.H. Jones, A. Lerman, J.P. McConnell, and H.S. Weintraub Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines Am J Cardiol 101 2008 51F 57F
34. M.A. Albert, R.J. Glynn, R.L. Wolfert, and P.M. Ridker The effect of statin therapy on lipoprotein associated phospholipase A2 levels Atherosclerosis 182 2005 193 198
35. Z. Qiao, J. Ren, and H. Chen Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits J Int Med Res 37 2009 1029 1037
36. S. Campo, M.A. Sardo, and A. Bitto Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals Clin Chem 50 2004 2077 2082
37. D.N. Kiortsis, S. Tsouli, E.S. Lourida, V. Xydis, M.I. Argyropoulou, M. Elisaf, and A.D. Tselepis Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia Angiology 56 2005 451 458
38. I. Yamamoto, J. Fujitsu, S. Nohnen, T. Igarashi, T. Motomura, M. Inaba, S. Tsubakimori, and J. Azuma Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients Diabetes Res Clin Pract 59 2003 219 224
39. S. Mansoub, M.K. Chan, and K. Adeli Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome Clin Biochem 39 2006 569 587